TNSN01169A1 - Compositions comprenant des agonistes de gaba et des inhibiteurs de sorbitol-deshydrogenase. - Google Patents

Compositions comprenant des agonistes de gaba et des inhibiteurs de sorbitol-deshydrogenase.

Info

Publication number
TNSN01169A1
TNSN01169A1 TNTNSN01169A TNSN01169A TNSN01169A1 TN SN01169 A1 TNSN01169 A1 TN SN01169A1 TN TNSN01169 A TNTNSN01169 A TN TNSN01169A TN SN01169 A TNSN01169 A TN SN01169A TN SN01169 A1 TNSN01169 A1 TN SN01169A1
Authority
TN
Tunisia
Prior art keywords
compositions
dehydrogenase inhibitors
sorbitol dehydrogenase
gaba agonists
precursors
Prior art date
Application number
TNTNSN01169A
Other languages
English (en)
Inventor
Lakshman Mylari Banavara
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN01169A1 publication Critical patent/TNSN01169A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSITIONS COMPRENANT UN AGONISTE DE GABA, OU UN DE SES PRECURSEURS MEDICAMENTEUX OU BIEN UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CET AGONISTE DE GABA OU DE CE PRECURSEUR MEDICAMENTEUX ET UN SDI OU UN DE SES PRECURSEURS MEDICAMENTEUX, OU BIEN UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CE SDI OU DE CES PRECURSEURS MEDICAMENTEUX. ELLE CONCERNE EGALEMENT DES KITS CONTENANT CES ASSOCIATIONS. APPLICATION : UTILISATION DES COMPOSITIONS POUR LE TRAITEMENT DES COMPLICATIONS DU DIABETE CHEZ DES MAMMIFERES, Y COMPRIS L'HOMME.
TNTNSN01169A 2000-11-30 2001-11-29 Compositions comprenant des agonistes de gaba et des inhibiteurs de sorbitol-deshydrogenase. TNSN01169A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25006900P 2000-11-30 2000-11-30

Publications (1)

Publication Number Publication Date
TNSN01169A1 true TNSN01169A1 (fr) 2005-11-10

Family

ID=22946187

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN01169A TNSN01169A1 (fr) 2000-11-30 2001-11-29 Compositions comprenant des agonistes de gaba et des inhibiteurs de sorbitol-deshydrogenase.

Country Status (38)

Country Link
US (1) US6544998B2 (fr)
EP (1) EP1337271B1 (fr)
JP (1) JP2004514699A (fr)
KR (1) KR20030059290A (fr)
CN (1) CN1477975A (fr)
AP (1) AP2001002360A0 (fr)
AR (1) AR031431A1 (fr)
AT (1) ATE281181T1 (fr)
AU (1) AU2002215159A1 (fr)
BG (1) BG107774A (fr)
BR (1) BR0115783A (fr)
CA (1) CA2430298A1 (fr)
CR (1) CR6964A (fr)
CZ (1) CZ20031399A3 (fr)
DE (1) DE60106968T2 (fr)
DO (1) DOP2001000289A (fr)
EA (1) EA200300432A1 (fr)
EC (1) ECSP034624A (fr)
EE (1) EE200300248A (fr)
ES (1) ES2230378T3 (fr)
HR (1) HRP20030420A2 (fr)
HU (1) HUP0302160A3 (fr)
IL (1) IL155704A0 (fr)
IS (1) IS6786A (fr)
MA (1) MA26964A1 (fr)
MX (1) MXPA03004870A (fr)
NO (1) NO20032441L (fr)
OA (1) OA12534A (fr)
PA (1) PA8534101A1 (fr)
PE (1) PE20020597A1 (fr)
PL (1) PL365927A1 (fr)
PT (1) PT1337271E (fr)
SK (1) SK6192003A3 (fr)
SV (1) SV2003000751A (fr)
TN (1) TNSN01169A1 (fr)
UY (1) UY27042A1 (fr)
WO (1) WO2002043762A2 (fr)
ZA (1) ZA200303381B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41920E1 (en) 1996-07-24 2010-11-09 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
CZ299755B6 (cs) * 2001-05-25 2008-11-12 Warner-Lambert Company Llc Kapalná farmaceutická kompozice obsahující analoggama-aminomáselné kyseliny, zpusob její prípravy a použití
CA2451267A1 (fr) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
AU2005231433A1 (en) * 2004-04-02 2005-10-20 Impax Laboratories, Inc. Controlled release dosage for GABA receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
PL1849773T3 (pl) 2005-02-17 2014-03-31 Astellas Pharma Inc Pochodne piperazyny do leczenia nietrzymania moczu i bólu
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
US20090176796A1 (en) 2007-04-27 2009-07-09 Purdue Pharma L. P. Trpv1 antagonists including amide substituent and uses thereof
EP2207569B1 (fr) * 2007-10-09 2013-03-27 Merck Patent GmbH Compositions pharmaceutiques contenant de la benfotiamine et un ou plusieurs agents pharmaceutiquement actifs pour le traitement d'états de douleur d'origine névropathique
EP2116618A1 (fr) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnostic et traitement de la maladie de Kawasaki
WO2011071995A2 (fr) 2009-12-08 2011-06-16 Case Western Reserve University Composés et procédés de traitement de troubles oculaires
WO2012050907A2 (fr) * 2010-09-28 2012-04-19 The Regents Of The University Of California Agonistes de gaba dans le traitement de troubles associés au syndrome métabolique et combinaisons de gaba dans le traitement ou la prophylaxie du diabète de type i
PE20141531A1 (es) 2011-06-22 2014-10-23 Purdue Pharma Lp Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
AU2020259406A1 (en) 2019-04-17 2021-11-04 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
EP0059987B1 (fr) 1979-06-01 1985-08-14 The Wellcome Foundation Limited Alpha-cyano-alpha-((N-guanidino)-imino)toluènes
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
EP0662962A1 (fr) * 1992-09-28 1995-07-19 Pfizer Inc. Pyrimidines substituees pour le controle des complications diabetiques
WO2000050034A1 (fr) * 1999-02-24 2000-08-31 The Regents Of The University Of California Les recepteurs alpha gaba assurent la mediation de l'inhibition des reponses des lymphocytes t
NZ514144A (en) * 1999-04-01 2001-09-28 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
ES2215570T3 (es) * 1999-04-01 2004-10-16 Pfizer Products Inc. Compuestos para tratar y prevenir complicaciones diabeticas.

Also Published As

Publication number Publication date
CZ20031399A3 (cs) 2004-04-14
KR20030059290A (ko) 2003-07-07
PA8534101A1 (es) 2002-10-31
ECSP034624A (es) 2003-07-25
PE20020597A1 (es) 2002-07-08
BR0115783A (pt) 2003-09-16
ES2230378T3 (es) 2005-05-01
MA26964A1 (fr) 2004-12-20
EP1337271B1 (fr) 2004-11-03
DE60106968T2 (de) 2005-11-03
NO20032441D0 (no) 2003-05-28
DOP2001000289A (es) 2003-02-15
AP2001002360A0 (en) 2001-12-31
BG107774A (en) 2004-01-30
AU2002215159A1 (en) 2002-06-11
CR6964A (es) 2004-02-02
EP1337271A2 (fr) 2003-08-27
ZA200303381B (en) 2004-04-30
CN1477975A (zh) 2004-02-25
ATE281181T1 (de) 2004-11-15
IS6786A (is) 2003-04-14
PT1337271E (pt) 2005-01-31
CA2430298A1 (fr) 2002-06-06
NO20032441L (no) 2003-07-03
SK6192003A3 (en) 2004-07-07
US6544998B2 (en) 2003-04-08
AR031431A1 (es) 2003-09-24
EE200300248A (et) 2003-10-15
HUP0302160A2 (hu) 2003-11-28
IL155704A0 (en) 2003-11-23
SV2003000751A (es) 2003-01-13
DE60106968D1 (de) 2004-12-09
WO2002043762A3 (fr) 2003-03-13
MXPA03004870A (es) 2003-08-19
JP2004514699A (ja) 2004-05-20
EA200300432A1 (ru) 2003-10-30
PL365927A1 (en) 2005-01-10
HRP20030420A2 (en) 2004-08-31
US20020091128A1 (en) 2002-07-11
OA12534A (en) 2006-06-05
UY27042A1 (es) 2002-07-31
HUP0302160A3 (en) 2005-05-30
WO2002043762A2 (fr) 2002-06-06

Similar Documents

Publication Publication Date Title
TNSN01169A1 (fr) Compositions comprenant des agonistes de gaba et des inhibiteurs de sorbitol-deshydrogenase.
TNSN01170A1 (fr) Associations d'agonistes de gaba et d'inhibiteurs d'aldose-reductase.
MA25820A1 (fr) Combinaisons d'inhibiteurs de peptidase iv de dipeptidyle et d'autres agents antidiabetiques pour le traitement du mellitus de diabete.
TNSN01017A1 (fr) Compositions comprenant un antibiotique azalide, et procedes pour leur preparation
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
HUP0004348A2 (hu) Vegyületek női szexuális diszfunkció kezelésére
TNSN01119A1 (fr) Compositions contenant des inhibiteurs de la proteine de transfert d'ester de cholesteryle
TNSN02037A1 (fr) Sulfonylpyridazinones nouvelles inhibitrices d'aldose reductase et compositions les contenant
TNSN98182A1 (fr) Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
TNSN01145A1 (fr) Derives d'imidazole a noyau aryle ou heteroaryle condense, et compositions les contenant.
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01166A1 (fr) Composes agonistes selectifs des recepteurs ep4 et compositions les contenant.
MA32539B1 (fr) Traitement du diabète chez des patients pour lesquels une thérapie par la metformine n'est pas appropriée
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN02014A1 (fr) Composes nouveaux agonistes de ppar et compositions les contenant
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2329636A1 (fr) Associations de riluzole et de levodopa pour le traitement de la maladie de parkinson
FI971207A0 (fi) Aromataasiestäjien käyttö miesten suhteellisen androgeeninpuutteen hoitamiseen tarkoitetun lääkkeen valmistukseen
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
ATE228849T1 (de) Behandlung des typ ii-deabetes mellitus mit amylinagonisten
PT867178E (pt) Utilizacao de agonistas nao alostericos de gaba para o tratamento de desordens do sono
BG105302A (en) Means for improving cognition
TNSN01046A1 (fr) Ethers de diphenyle utiles en therapeutique